Lexington Biosciences Comments on Recent Trading Activity

VANCOUVER, BC--(Marketwired - Nov 1, 2017) - Lexington Biosciences, Inc. (CSE: LNB) (CSE: LNB.CN) (CNSX: LNB) (OTCQB: LXGTF) (the "Company" or "Lexington") is issuing this press release at the request of the OTC Markets Group Inc.

On October 17, 2017, the Company's management became aware of certain promotional materials that were published by Techstock Insider that were purportedly paid for by Ellis Stewart LLC. The Company wishes to advise investors that they should only rely on information provided to the market by the Company and does not support or endorse the information in the materials published on this website. For information about the Company investors should go to the Company's website at www.lexingtonbiosciences.com or review the Company's public disclosure record available at www.sedar.com. Lexington did not pay for or review the materials published by Techstock Insider and does not have any relationship with Ellis Stewart LLC. The Company notes that the materials are inaccurate in a number of places including describing the Company's principal product, HeartSentry, as "biometric" and "wearable." HeartSentry is best described as a "cardiovascular diagnostic medical device."

The Company has engaged the following groups to provide investor relation and marketing services: Renmark Financial Communications Inc., Hybrid Financial Ltd and Audience Marketing (the "Third Party Service Providers").

The Company further notes that none of the Company's management, directors or Third Party Service Providers has sold any shares of the Company in the last 90 days. 

At the request of OTC Markets Group the Company confirms that in the last 12 months it has issued the following securities at the following prices: (a) 6,250,000 units (consisting of a share plus one half warrant) at $0.20 per unit; and (b) 2,530,000 units (consisting of a share plus a whole warrant) at $0.25 per unit.

About Lexington Biosciences, Inc.

Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium -- the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

Eric Willis
CEO & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.